Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,664.63
(
-0.77%
)
US TECH 100
24,003.60
(
-0.53%
)
Dow Jones
46,534.42
(
-0.98%
)
Brent Oil
105.66
(
4.97%
)
Bitcoin
71,285.10
(
-3.59%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 162078

Monday, 06/03/2013 6:40:03 PM

Monday, June 03, 2013 6:40:03 PM

Post# of 257253
PTLA—There’s nothing wrong with Betrixaban per se, but it’s not differentiated from Eliquis (or Xarelto) and it’s very late to market even in the best-case scenario. That’s why MRK pulled out of the partnership to develop Betrixaban two years ago (#msg-61300408).

If PTLA would scrap Betrixaban and focus only on extracting maximum value for PRT-4445, I would be more inclined to invest.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now